2011-11-20 个体化治疗时代多靶点药物究竟何去何从 多靶点药物治疗非小细胞肺癌最新临床进展综述_周彩存.pdfVIP

874 · · 中国肺癌杂志2 0 1 1 年 1 1月第 1 4卷第 1 1期 Chin J Lung Cancer, November 2011, Vol.14, No.11 DOI: 10.3779/j.issn.1009-3419.2011.11.08 · 综 述 · 个体化治疗时代多靶点药物究竟何去何从 ——多靶点药物治疗非小细胞肺癌 最新临床进展综述 周彩存 【摘要 】 目前在非小细胞肺癌治疗中，多靶点药物占有举足轻重的地位。近年来随着多项III期临床结果的陆 续公布，多靶点药物的疗效可谓喜忧参半。在个体化治疗的大方向下，如何发挥多靶点药物的最佳疗效，的确值得 我们探索。本文综述了近年来多靶点药物治疗非小细胞肺癌的最新临床进展，希望能有所启发。 【关键词 】肺肿瘤；多靶点药物；舒尼替尼；索拉非尼；凡德他尼；Crizotinib R734.2 【中图分类号 】 Current Status and Future Direction of Multi-targeted Drugs in the Era of Personalized Therapy —Overview of Advances in Multi-targeted Therapy in Non-small Cell Lung Cancer Caicun ZHOU Department of Oncology, Shanghai Pulmonary Hospital, Affiliated to Tongji University School of Medicine, Shanghai 200433, China Corresponding author: Caicun ZHOU, E-mail: caicunzhou@ Abstract Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell 【 】 lung cancer (NSCLC). Recently, results of several large phase III studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC.. Key words Lung neoplasms; Multi-targeted tyrosine kinase inhibitor; Sunitinib; Sorafenib; Vandetanib; Crizotinib